Search - tctmd.com

Displaying 321 - 340 of 373

Sort: Relevancy | Date

News Daily News

APPOSITION II Published: Self-Expanding Stent Performs Well in STEMI Patients

December 17, 2012

News Daily News

APPOSITION II Publicado: El Stent Auto Expandible Funciona Bien en Pacientes STEMI

December 17, 2012

News Daily News

Su Publica el PACIFIER: Los Balones liberadores de Fármacos Ayudan a tratar las Lesiones Femoropoplíteas

Caitlin E. Cox

December 09, 2012

News Daily News

PACIFIER Published: Drug-Eluting Balloon Helps Treat Femoropopliteal Lesions

Caitlin E. Cox

December 09, 2012

News Daily News

Zilver Stent Seen as Welcome Addition to PAD Armamentarium

L.A. McKeown

November 25, 2012

News Daily News

Stent Zilver parece ser una adición bienvenida al arsenal de PAD

L.A. McKeown

November 25, 2012

News Industry News

Cook Medical’s Zilver® PTX® Earns FDA Approval As First Drug-Eluting Stent in U.S. to Treat Peripheral Arterial Disease

November 14, 2012

Presentation TCT 2012

Role of DCB in SFA Intervention: Predictions Five Years into the Future

Presenter: Thomas Zeller

October 25, 2012

Presentation TCT 2012

SFA Intervention: State of the Art Today and in 2020

Presenter: Gary Ansel

October 24, 2012

News Conference News TCT 2012

DEBATE-SFA Favors Predilatation with Drug-Eluting Balloon Before BMS

October 24, 2012

Presentation TCT 2012

What is the Current Role of Metal Prostheses in the SFA? Master Perspectives

Presenter: Giancarlo Biamino

October 22, 2012

Presentation TCT 2012

Update on Important SFA Therapies: VIBRANT, VIPER and Zilver PTX Studies

Presenter: Gary Ansel

October 22, 2012

Presentation TCT 2012

Drug-Coated Balloons for SFA In-Stent Restenosis: A Simple Solution for a Tenacious Problem?

Presenter: Eugenio Stabile

October 22, 2012

Presentation TCT 2012

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Pro!

Presenter: Gary Ansel

October 22, 2012

Presentation TCT 2012

Adventitial Injection for SFA Restenosis: Results of an Exploratory Study

Presenter: Christopher Owens

October 22, 2012

Presentation TCT 2012

What is the Potential Economic Impact of Antiproliferative Technologies in the SFA?

Presenter: Mark Burket

October 22, 2012

News Industry News

IDEV Presents Consistent Evidence Validating the Mimetic Design of SUPERA® Stent

October 22, 2012

Presentation TCT 2012

Development of a Bioabsorbable Scaffold for the SFA

Presenter: Richard Rapoza

October 22, 2012

Presentation TCT 2012

DEBATE-SFA: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty Prior to Nitinol Stenting in Patients with SFA and Popliteal Lesions

Presenter: Francesco Liistro

October 22, 2012

Presentation TCT 2012

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Con!

Presenter: Lawrence Garcia

October 22, 2012

Advertisement

APPOSITION II Published: Self-Expanding Stent Performs Well in STEMI Patients

APPOSITION II Publicado: El Stent Auto Expandible Funciona Bien en Pacientes STEMI

Su Publica el PACIFIER: Los Balones liberadores de Fármacos Ayudan a tratar las Lesiones Femoropoplíteas

PACIFIER Published: Drug-Eluting Balloon Helps Treat Femoropopliteal Lesions

Zilver Stent Seen as Welcome Addition to PAD Armamentarium

Stent Zilver parece ser una adición bienvenida al arsenal de PAD

Cook Medical’s Zilver® PTX® Earns FDA Approval As First Drug-Eluting Stent in U.S. to Treat Peripheral Arterial Disease

Role of DCB in SFA Intervention: Predictions Five Years into the Future

SFA Intervention: State of the Art Today and in 2020

DEBATE-SFA Favors Predilatation with Drug-Eluting Balloon Before BMS

What is the Current Role of Metal Prostheses in the SFA? Master Perspectives

Update on Important SFA Therapies: VIBRANT, VIPER and Zilver PTX Studies

Drug-Coated Balloons for SFA In-Stent Restenosis: A Simple Solution for a Tenacious Problem?

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Pro!

Adventitial Injection for SFA Restenosis: Results of an Exploratory Study

What is the Potential Economic Impact of Antiproliferative Technologies in the SFA?

IDEV Presents Consistent Evidence Validating the Mimetic Design of SUPERA® Stent

Development of a Bioabsorbable Scaffold for the SFA

DEBATE-SFA: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty Prior to Nitinol Stenting in Patients with SFA and Popliteal Lesions

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Con!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content